by Team PCM | May 23, 2023 | Blog post, Drug Pricing
Drug shortages are at a ten-year high, challenging patients and healthcare providers. These shortages occur when the demand for a particular medication exceeds the available supply, leading to potential delays or unavailability of essential drugs. Plan sponsors have a...
by Team PCM | Mar 21, 2023 | Blog post, Drug Pricing
The 2023 growth may be small, but drug exclusion lists are still growing for the three largest pharmacy benefit managers (PBMs). Handling over 80% of all prescriptions filled in the United States, the exclusion lists for these PBMs are widening the gap between list...
by Team PCM | Jan 6, 2023 | Blog post, Drug Pricing
Switching from an expensive brand-name medication to a lower-cost generic alternative is a proven savings strategy self-insured plan sponsors employ to reduce plan and participant costs. However, plans may miss significant savings by focusing only on brand-to-generic...
by Team PCM | Oct 24, 2022 | Blog post, Drug Pricing
The passage of the Inflation Reduction Act (IRA) in August 2022 will impact patients, providers, and benefit plan sponsors by disrupting drug pricing. The IRA allows the Department of Health and Human Services to negotiate specific drug prices for the Medicare...
by Team PCM | Sep 14, 2022 | Blog post, Biosimilars, Drug Pricing
Biosimilar drugs are “highly similar to” and have “no clinically meaningful differences” from existing FDA-approved biologics. Currently, there are 38 biosimilars on the market, giving patients safe, cost-effective alternatives to high-cost biologics. Adoption of...
by Team PCM | Jul 21, 2022 | Blog post, Drug Pricing
One in ten people in the United States has diabetes. $1 in $4 of US healthcare costs is spent caring for people with diabetes, resulting in a 26% increase in the cost of diagnosed diabetes from $245 billion in 2012 to $327 billion in 2017. Hospital inpatient care, the...
